Intrexon (XON) Trading Down 5.9%

Intrexon Corp (NYSE:XON)’s share price dropped 5.9% during mid-day trading on Thursday . The company traded as low as $14.82 and last traded at $15.11. Approximately 1,522,776 shares were traded during trading, a decline of 4% from the average daily volume of 1,581,261 shares. The stock had previously closed at $16.05.

XON has been the subject of a number of research reports. Stifel Nicolaus initiated coverage on Intrexon in a report on Tuesday, July 17th. They set a “buy” rating and a $72.00 target price for the company. Zacks Investment Research upgraded shares of Intrexon from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a research note on Thursday, August 16th. Bank of America downgraded shares of Intrexon from a “neutral” rating to an “underperform” rating and set a $12.00 price objective for the company. in a research note on Monday, July 16th. ValuEngine upgraded shares of Intrexon from a “strong sell” rating to a “sell” rating in a research note on Monday, August 20th. Finally, JMP Securities increased their price objective on shares of Intrexon from $42.00 to $43.00 and gave the stock a “market outperform” rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $29.67.

The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.53 and a current ratio of 1.78. The company has a market capitalization of $2.47 billion, a P/E ratio of -16.43 and a beta of 1.09.

Intrexon (NYSE:XON) last posted its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.51) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.28). Intrexon had a negative return on equity of 16.67% and a negative net margin of 82.17%. The business had revenue of $45.30 million for the quarter, compared to analyst estimates of $51.70 million. During the same quarter in the prior year, the company earned ($0.16) earnings per share. On average, equities research analysts forecast that Intrexon Corp will post -0.79 EPS for the current year.

In other news, insider Helen Sabzevari sold 8,402 shares of the stock in a transaction dated Wednesday, July 18th. The shares were sold at an average price of $14.54, for a total transaction of $122,165.08. Following the completion of the transaction, the insider now directly owns 25,000 shares in the company, valued at approximately $363,500. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 48.20% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Northern Trust Corp lifted its stake in Intrexon by 123.1% in the 2nd quarter. Northern Trust Corp now owns 917,510 shares of the biotechnology company’s stock valued at $12,791,000 after purchasing an additional 506,186 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Intrexon by 18.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 278,611 shares of the biotechnology company’s stock valued at $3,884,000 after purchasing an additional 43,310 shares during the last quarter. California Public Employees Retirement System lifted its stake in Intrexon by 96.3% in the 2nd quarter. California Public Employees Retirement System now owns 58,632 shares of the biotechnology company’s stock valued at $817,000 after purchasing an additional 28,762 shares during the last quarter. Peloton Wealth Strategists lifted its stake in Intrexon by 12.7% in the 2nd quarter. Peloton Wealth Strategists now owns 39,900 shares of the biotechnology company’s stock valued at $556,000 after purchasing an additional 4,500 shares during the last quarter. Finally, MetLife Investment Advisors LLC acquired a new stake in Intrexon in the 2nd quarter valued at about $457,000. Institutional investors and hedge funds own 84.92% of the company’s stock.

About Intrexon (NYSE:XON)

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Read More: What are the benefits of buying treasury bonds?

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply